SubHero Banner
Text

Taclonex® (calcipotriene/betamethasone dipropionate) – Expanded indication

July 31, 2019 - Leo Pharma announced the FDA approval of Taclonex (calcipotriene/betamethasone dipropionate) topical suspension, for the topical treatment of plaque psoriasis of the scalp and body in patients 12 years and older.

Download PDF